Free tool
Drug Trial Radar: Ophthalmology
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
188
Completed, industry sponsors, Ophthalmology, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed188
188 trials
Showing 1 to 25, recently updated first.
BayerBayer (BAYRY)
NCT06591598 · 51 participants · Start Sep 2, 2024 · Primary completion Oct 14, 2025
Drug: Aflibercept (BAY86-5321, Eylea) · For: Diabetic Macular Edema; Neovascular Age-related Macular Degeneration
Sites: Prague, Czechia; Budapest, Hungary; Debrecen, Hungary · 6 sites in all
Bio-Thera SolutionsIndustry
NCT05180526 · 60 participants · Start Dec 27, 2021 · Primary completion Aug 5, 2025
Drug: QLETLI · For: Uveitis
Sites: Beijing, China; Changsha, China; Chongqing, China · 7 sites in all
Harrow IncIndustry
NCT07588074 · 40 participants · Start May 1, 2021 · Primary completion Jun 30, 2021
Drug: Fluorometholone Acetate Ophthalmic Suspension 0.1%; Loteprednol Etabonate Ophthalmic Gel 0.38% · For: Ocular Inflammation; Keratoconjunctivitis; Dry Eye Disease (DED) and 4 more
Sites: Baton Rouge, Louisiana
- A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With CyclosporinePivotal-lookingCompleted
Novaliq GmbHIndustry
NCT06329661 · 204 participants · Start Apr 22, 2024 · Primary completion Jul 30, 2025
Drug: Cyclosporine ophthalmic solution, 0.1%; Saline solution, 0.6% · For: Dry Eye Disease; Endothelial Cell
Sites: Newport Beach, California; Torrance, California; Garner, North Carolina · 6 sites in all
- A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory TreatmentPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07025811 · 378 participants · Start Jul 9, 2025 · Primary completion Jul 16, 2026
Drug: Vevye®; Xiidra® · For: Dry Eye Disease
Sites: Newport Beach, California; Louisville, Kentucky; Andover, Massachusetts · 8 sites in all
Bausch & Lomb IncorporatedIndustry
NCT06346340 · 97 participants · Start Apr 30, 2024 · Primary completion Feb 24, 2025
Drug: Miebo · For: Dry Eye
Sites: Laguna Hills, California; Petaluma, California; Sacramento, California · 12 sites in all
NCT03020992 · 89 participants · Start Dec 21, 2016 · Primary completion Dec 4, 2019
Drug: Certolizumab Pegol · For: Axial Spondyloarthritis (axSpA); Anterior Uveitis (AU)
Sites: Brno, Czechia; Ostrava, Czechia; Pardubice, Czechia · 23 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05959304 · 66 participants · Start Dec 11, 2024 · Primary completion Nov 17, 2025
Drug: brolucizumab · For: Diabetic Macular Edema
Sites: Ahmedabad, India; Bangalore, India; Kochi, India · 8 sites in all
- Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.Pivotal-lookingCompleted
Laboratorios Sophia S.A de C.V.Industry
NCT04702776 · 182 participants · Start Dec 9, 2021 · Primary completion May 15, 2023
Drug: Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%; Sodium hyaluronate 0.15% and 1 more · For: Dry Eye
Sites: Guadalajara, Mexico
Bausch & Lomb IncorporatedIndustry
NCT07054606 · 104 participants · Start Jul 2, 2025 · Primary completion Nov 3, 2025
Drug: Perfluorohexyloctane ophthalmic solution · For: Dry Eye
Sites: San Diego, California; Longwood, Florida; Pittsburg, Kansas · 6 sites in all
PharmasoftIndustry
NCT06437639 · 80 participants · Start Sep 15, 2023 · Primary completion Nov 29, 2023
Drug: Mexidol · For: Primary Open-Angle Glaucoma (POAG)
Sites: Tyumen, Russia
Bausch & Lomb IncorporatedIndustry
NCT06309953 · 99 participants · Start Feb 28, 2024 · Primary completion Jun 17, 2024
Drug: Miebo · For: Dry Eye
Sites: Birmingham, Alabama; Petaluma, California; Pittsburg, Kansas · 7 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04679935 · 52 participants · Start Jul 13, 2021 · Primary completion Jan 31, 2024
Drug: Brolucizumab · For: Age-related Macular Degeneration
Sites: Regensburg, Germany; Frankfurt am Main, Germany; Berlin, Germany · 19 sites in all
BayerBayer (BAYRY)
NCT05511038 · 100 participants · Start Aug 26, 2022 · Primary completion Apr 16, 2024
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) · For: Diabetic Macular Edema
Sites: Hyderabad, India; Ahmedabad, India; Bengaluru, India · 10 sites in all
- Effects of NOV03 on the Tear FilmCompleted
Bausch & Lomb IncorporatedIndustry
NCT05723770 · 33 participants · Start Aug 14, 2023 · Primary completion Dec 23, 2023
Drug: instillation of NOV03 · For: Dry Eye Disease (DED)
Sites: Miami, Florida
AbbVieAbbVie (ABBV)
NCT05414201 · 87 participants · Start Jul 7, 2022 · Primary completion Jun 10, 2024
Drug: Adalimumab · For: Non-infectious Intermediate Posterior- or Pan-uveitis
Sites: Beijing, China; Shanghai, China; Hangzhou, China · 7 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04774926 · 122 participants · Start Oct 15, 2021 · Primary completion Oct 4, 2023
Drug: Brolucizumab · For: Neovascular Age-related Macular Degeneration
Sites: Ancona, Italy; Acquaviva delle Fonti, Italy; Bologna, Italy · 20 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05269966 · 105 participants · Start Mar 9, 2022 · Primary completion Aug 29, 2023
Drug: Injection Brolucizumab · For: Neovascular Age-related Macular Degeneration (nAMD)
Sites: Asarwa, India; Ahmedabad, India; Bangalore, India · 10 sites in all
Formycon AGIndustry
NCT06708637 · 30 participants · Start Sep 20, 2024 · Primary completion Oct 8, 2024
Drug: FYB203 2 mg (0.05 mL of 40 mg/mL) · For: Age-Related Macular Degeneration; Branch Retinal Vein Occlusion with Macular Edema; Central Retinal Vein Occlusion with Macular Edema and 2 more
Sites: Campbell, California; Long Beach, California; Redlands, California · 4 sites in all
Formycon AGIndustry
NCT06708624 · 31 participants · Start Jun 11, 2024 · Primary completion Aug 8, 2024
Drug: FYB201 0.5 mg (0.05 mL of 10 mg/mL) · For: Age-Related Macular Degeneration; Branch Retinal Vein Occlusion with Macular Edema; Central Retinal Vein Occlusion with Macular Edema
Sites: Campbell, California; Long Beach, California; Hagerstown, Maryland · 4 sites in all
Laboratorios PoenIndustry
NCT05857267 · 84 participants · Start Mar 7, 2023 · Primary completion Nov 4, 2024
Drug: Dorzolamide / Timolol Ophthalmic Solution; dorzolamide/timolol · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Olivos, Argentina; Ciudad Autonoma de Buenos Aire, Argentina; Ciudad Autónoma de Buenos Aire, Argentina · 6 sites in all
Research Insight LLCIndustry
NCT06482177 · 52 participants · Start Oct 12, 2023 · Primary completion Jun 5, 2024
Drug: Cyclosporine ophthalmic solution · For: Dry Eye
Sites: Laguna Hills, California
Santen SASIndustry
NCT03237936 · 17 participants · Start Mar 28, 2017 · Primary completion Jul 11, 2018
Drug: 1mg/mL ciclosporin · For: Keratitis
Sites: Brest, France
- Rocklatan® EvaluationCompleted
Aerie PharmaceuticalsIndustry
NCT05283395 · 136 participants · Start Mar 28, 2022 · Primary completion Mar 22, 2023
Drug: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution · For: Glaucoma
Sites: Mission Hills, California; Newport Beach, California; Pasadena, California · 21 sites in all
Sun Pharmaceutical Industries LimitedIndustry
NCT04357795 · 135 participants · Start Jun 29, 2020 · Primary completion Jun 24, 2022
Drug: CequaTM (Cyclosporine 0.09%) ophthalmic solution · For: Dry Eye Disease
Sites: Fort Myers, Florida; Jacksonville, Florida; Panama City, Florida · 5 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.